Outlook Therapeutics Says FDA Acknowledged Receipt Of Co's BLA Resubmission - SEC Filing
April 8 (Reuters) - Outlook Therapeutics Inc OTLK.O:
OUTLOOK THERAPEUTICS INC - FDA ACKNOWLEDGES RECEIPT OF OUTLOOK THERAPEUTICS' BLA RESUBMISSION - SEC FILING
OUTLOOK THERAPEUTICS INC - FDA SETS PDUFA GOAL DATE OF AUGUST 27, 2025 - SEC FILING
OUTLOOK THERAPEUTICS - FDA DETERMINED CLASS 2 REVIEW FOR OUTLOOK THERAPEUTICS' BLA FOR ONS-5010- SEC FILING
Source text: [ID:n0001558370-25-004606]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Nebius Stock: Can This AI Infrastructure Play Really Double in 2026?

Google Bets $40B on Anthropic: Is Google Cloud the New Growth Engine as Meta Challenges Ad Dominance?

Semiconductor Sector Continues to Rise, Should Retail Investors Buy Intel or AMD?
Intel Posts Best Day Since 1987 as Nvidia Market Cap Reclaims $5 Trillion: Is the AI Trade Overstretched?

Amazon 2026 Q1 Earnings Preview: AWS and Advertising Dual Engines Power Ahead, Can They Allay Market Doubts?

Tradingkey








